Volume 39, Issue 6 pp. 586-593
Research Article

Localised Ewing sarcoma/PNET of bone—prognostic factors and international data comparison

R. Derek Jenkin FRCP(C)

Corresponding Author

R. Derek Jenkin FRCP(C)

Department of Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

Section of Radiation Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

Section of Radiation Oncology, MBC 34, King Faisal Specialist Hospital and Research Centre, PO Box 3354, Riyadh, Saudi Arabia 11211.Search for more papers by this author
Ibrahim Al-Fawaz FRCP(C)

Ibrahim Al-Fawaz FRCP(C)

Department of Pediatric Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

Search for more papers by this author
Mohammed Al-Shabanah FRCP(C)

Mohammed Al-Shabanah FRCP(C)

Department of Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

Section of Radiation Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

Search for more papers by this author
Ayman Allam MD

Ayman Allam MD

Department of Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

Section of Radiation Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

Search for more papers by this author
Mouhab Ayas MD

Mouhab Ayas MD

Department of Pediatric Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

Search for more papers by this author
Yasser Khafaga MD

Yasser Khafaga MD

Department of Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

Section of Radiation Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

Search for more papers by this author
Muhammad Memon MD

Muhammad Memon MD

Department of Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

Section of Medical Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

Search for more papers by this author
Samira Rifai MD

Samira Rifai MD

Department of Pediatric Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

Search for more papers by this author
Henrik Schultz MD

Henrik Schultz MD

Department of Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

Section of Radiation Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

Search for more papers by this author
Derek Younge FRCS(C)

Derek Younge FRCS(C)

Department of Orthopedic Surgery, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

Search for more papers by this author
First published: 09 October 2002
Citations: 30

Abstract

Background

To determine if the distribution of prognostic factors accounted for the differences when the outcome for localised Ewing Sarcoma/PNET bone in Saudi Arabia was compared with results from countries with well developed health care systems.

Procedure

Retrospective analysis was undertaken of 163 consecutive patients of all ages, treated with radical intent at KFSHRC from 1975 to 1998. Standard chemotherapy was commenced in all patients. The local treatment modality was resection ± radiation in 30% and radiation treatment alone in 67%. Size data were available for 51 patients treated from 1994 to 1998, inclusive. One third of these patients had tumors with volume >500 ml.

Results

Three year survival significantly increased with the year of diagnosis, 1975–1988 45%; 1989–1993 55%; and 1993–1998 63% (P = 0.006). Favorable prognostic factors were age ≤14 (P = 0.07); site, distal extremity, and skull (P = 0.08); and volume ≤ 200 ml (P = 0.06). Secondary prognostic factors were response to induction chemotherapy, both histological, 100% necrosis, (P = 0.04) and clinical CR+PR, (P = 0.02). From 1994 to 1998, 3 year survival for tumors in the distal extremity and skull was 80% and for small tumors, < 200 ml, at any site was 82%. In comparison, the 3 year survival for patients with tumors at any other sites was 60%, and for tumors >200 ml, 55%.

Conclusions

Overall survival progressively improved. From 1994 to 1998 the survival of patients with small tumors and/or favorable sites was similar to the best reported results. It was not possible to compare results by tumor size for large tumors, > 500 ml, due to the absence of data from elsewhere. A better staging system is required for the international comparison of results. Med Pediatr Oncol 2002;39:586–593. © 2002 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.